Chemistry:Vilaprisan
From HandWiki
Revision as of 07:22, 12 August 2021 by imported>MainEditor
 | |
| Clinical data | |
|---|---|
| Other names | BAY-1002670; 17β-Hydroxy-11β-[4-(methylsulfonyl)phenyl]-17α-(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one |
| Routes of administration | By mouth |
| Drug class | Selective progesterone receptor modulator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C27H29F5O4S |
| Molar mass | 544.58 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Vilaprisan (INN, USAN) (developmental code name BAY-1002670) is a synthetic and steroidal selective progesterone receptor modulator (SPRM) which is under development by Bayer HealthCare Pharmaceuticals for the treatment of endometriosis and uterine fibroids.[1][2][3] It is a potent and highly selective partial agonist of the progesterone receptor (PR).[4][2][3] As of 2017, the drug is in phase II clinical trials for the aforementioned indications.[1]
See also
- List of investigational hormonal agents § Progestogenics
- Lonaprisan
- Mifepristone
- Onapristone
- Ulipristal acetate
References
- ↑ 1.0 1.1 http://adisinsight.springer.com/drugs/800033040
- ↑ 2.0 2.1 "Selective progesterone receptor modulators". Curr. Opin. Obstet. Gynecol. 26 (4): 237–42. 2014. doi:10.1097/GCO.0000000000000082. PMID 24950125.
- ↑ 3.0 3.1 "Innovations in classical hormonal targets for endometriosis". Expert Rev Clin Pharmacol 9 (2): 317–27. 2016. doi:10.1586/17512433.2016.1129895. PMID 26645363.
- ↑ "Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women". Hum. Reprod. 31 (8): 1703–12. 2016. doi:10.1093/humrep/dew140. PMID 27288475.
External links
 |  |
